In April 2018, the US Food and Drug Administration (FDA) made a momentous decision. The agency's approval of IDx-DR, a diagnostic system developed by Iowa-based IDx Technologies for diabetic retinopathy, wasn't a revolutionary move on the face of it, but nevertheless marked an important inflection point in the delivery of modern healthcare. So why was the FDA's decision to award marketing clearance to IDx-DR so significant? As is increasingly the case in medical technology, the answer lies with artificial intelligence (AI). The IDx-DR software is driven by AI, and it's the first system approved to autonomously provide diagnostic assessments without the supervision of an expert clinician. The system involves capturing images of a patient's eye with a retinal camera – in this case the Topcon NW400 – that can be operated by any non-specialist staff member with a little training.

Machine learning has the potential to be extremely useful in medicine, particularly in the interpretation of medical images. But it also has inherent limitations, especially when it comes to diagnosing early-stage cancer.

In these online tools, patients input their initial symptoms and then proceed to answer a series of questions that the system deems relevant to those symptoms. The output of these online tools is a differential diagnosis (ranked list of diseases) that helps educate patients on possible relevant health conditions. Online symptom checkers are powered by underlying diagnosis models or engines similar to those used for advising physicians in "clinical decision support tools"; the main difference in this scenario being that the resulting differential diagnosis is not directly shared with the patient, but rather used by a physician for professional evaluation. Diagnosis models must have high accuracy while covering a large space of symptoms and diseases to be useful to patients and physicians. Accuracy is critically important, as incorrect diagnoses can give patients unnecessary cause for concern.

Decision Trees are great and are useful for a variety of tasks. They form the backbone of most of the best performing models in the industry like XGboost and Lightgbm. But how do they work exactly? In fact, this is one of the most asked questions in ML/DS interviews. We generally know they work in a stepwise manner and have a tree structure where we split a node using some feature on some criterion.

Partial Dependence Plots (PDPs) are a standard model inspection technique. It turns out that for decision trees, they can be computed very efficiently. This post explains how PDPs are computed in general, and goes into the details of the optimized version for tree models.

Artificial intelligence (AI) is expected to occupy an increasingly important place in diagnostic tasks in health care. The principles underlying learning are similar for human and artificial intelligences, but the respective approaches to diagnosis are markedly different. Clinicians approach diagnosis in an intuitive and deductive manner, whereas AI is chiefly analytical and inductive. The wholesale replacement of human intelligence by AI in diagnostic tasks is unlikely, apart from some highly targeted tasks; instead, AI should be considered as a tool to help clinicians in their reasoning. Artificial intelligence (AI) is often presented as the future of medical practice.

Health care is a complex adaptive system(1). Clinical diagnosis is one aspect of this system and is an additional layer of sophistication, as it relies on complex interactions between clinician and patient. Making a diagnosis is often a'process' rather than an'event'. It involves aspects of deductive reasoning, hypothesis testing, intuitive thought and pattern recognition; in addition to re-testing on the basis of new information provided by patient responses, physical examination, laboratory results and radiographic imaging (2,3,4). Pre-hospital care, primary care and care delivered in emergency departments involves the fullest possible range of clinical diagnostic acumen, as these settings provide advice and treatment on completely undifferentiated patients.

Decision Trees are a type of supervised learning used for classification (yes/no) and regression (continuous data) where the data is continuously split according to a certain parameter. The predicted class is derived from features of the data. The following article creates a Decision Tree from the 311 on 3.11 Project. In this project, the resolution outcome being positive or negative is what is being predicted. Agency: NYPD, Dept of Transportation, Dept of Health & Mental Hygiene, Dept of Sanitation, Dept of Housing Preservation and Development, Dept of Parks and Recreation, etc Borough: Brooklyn, Queens, Manhattan, Bronx, Staten Island Location: Longitude/Latitude, Cross Streets, Intersections Created/Closed Date Complaint Type: Heat/Hot Water, Rodent, Noise, Street Condition, Illegal Parking, Unsanitary Condition, Blocked Driveway are just a few examples.

Gradient Boosting Decision Trees (GBDTs) have become very successful in recent years, with many awards in machine learning and data mining competitions. There have been several recent studies on how to train GBDTs in the federated learning setting. In this paper, we focus on horizontal federated learning, where data samples with the same features are distributed among multiple parties. However, existing studies are not efficient or effective enough for practical use. They suffer either from the inefficiency due to the usage of costly data transformations such as secure sharing and homomorphic encryption, or from the low model accuracy due to differential privacy designs. In this paper, we study a practical federated environment with relaxed privacy constraints. In this environment, a dishonest party might obtain some information about the other parties' data, but it is still impossible for the dishonest party to derive the actual raw data of other parties. Specifically, each party boosts a number of trees by exploiting similarity information based on locality-sensitive hashing. We prove that our framework is secure without exposing the original record to other parties, while the computation overhead in the training process is kept low. Our experimental studies show that, compared with normal training with the local data of each owner, our approach can significantly improve the predictive accuracy, and achieve comparable accuracy to the original GBDT with the data from all parties.

The "Innovations in Cancer Diagnosis and Treatment, Micro-LEDs, Renewable Energy Generation and Storage, and Fault Detection" report has been added to ResearchAndMarkets.com's offering. The edition also provides insights on the role of macropinocytosis in pancreatic cancer. The TOE covers use of ceramic electrodes for doubling energy density and a biosensor for earlier diagnosis of tumors.